Alzheimer's disease is widely understood as a disorder of memory, but for a substantial share of patients it also brings something far more frightening: psychosis. People develop hallucinations, seeing or hearing things that are not there, and delusions, holding fixed false beliefs such as the conviction that a spouse is an impostor or that caregivers are stealing from them. These symptoms are among the most distressing features of the disease for families, and they often precipitate the move into institutional care. There is no FDA-approved drug specifically for Alzheimer's disease psychosis, and the antipsychotics borrowed from other conditions carry serious risks in elderly dementia patients. That gap is the target of ACADIA Pharmaceuticals' trial NCT06159673, testing a drug called ACP-204.
The short version is this: ACP-204 is an oral, once-daily compound designed to quiet an overactive serotonin signal in the brain that is implicated in psychosis, and ACADIA is testing it in a large, carefully staged study that the registry describes as a master protocol. The trial was last updated on June 12, 2026, is currently recruiting, and has a planned enrollment of 1,074 participants aged 55 to 95.
How ACP-204 is supposed to work
The registry describes ACP-204 as a potent and selective antagonist and inverse agonist of the serotonin 5-HT2A receptor. To unpack that: serotonin is a brain-signaling chemical, and the 5-HT2A receptor is one of the docks it binds to. Overactivity at this receptor is strongly linked to hallucinations and delusions. An antagonist blocks the receptor so serotonin cannot switch it on; an inverse agonist goes further and actively pushes the receptor below its resting baseline activity. In plain terms, ACP-204 is trying to turn down a specific volume knob that, when stuck too high, produces psychotic symptoms, rather than broadly sedating the brain the way older antipsychotics do.
This mechanism is not arbitrary for ACADIA. The company built its identity around 5-HT2A pharmacology in neuropsychiatric disease, and ACP-204 represents a next-generation swing at the same biological target. The promise of a selective approach is symptom control without the heavy sedation, movement side effects, and elevated mortality risk that make conventional antipsychotics so problematic in dementia.
The master-protocol design, explained
The most distinctive feature of this trial is its structure. Rather than running separate, sequential trials, ACADIA folded everything into one master protocol containing three independent, seamlessly enrolling, double-blind, placebo-controlled substudies. Here is how they fit together. Substudy 1 is the Phase 2 portion; it evaluates efficacy and dose response of ACP-204 at 30 mg and 60 mg against placebo, and it launches first. Substudies 2A and 2B are both Phase 3 confirmatory studies that begin after Substudy 1 has enrolled, and they are designed to independently confirm the benefit of the doses carried forward. The registry lists three arms reflecting this: ACP-204 30 mg, ACP-204 60 mg, and matching placebo, all taken once daily with or without food.
Think of it as building the dose-finding and the confirmation onto one continuous assembly line instead of stopping, breaking down the equipment, and starting over. The benefit is speed and efficiency: a single operational infrastructure, a smooth handoff from dose selection to confirmation, and no wasted gap between phases. The trial is described as quadruple-masked, the most rigorous blinding level, which means participants, care providers, investigators, and outcome assessors are all kept unaware of who is getting drug versus placebo, a crucial safeguard when the endpoint is a subjective symptom rating.
What the trial measures
The primary endpoint is the change from baseline at week 6 in the SAPS-H+D total score, the hallucinations and delusions subscales of the Scale for the Assessment of Positive Symptoms. This instrument is the standard, validated way to quantify the severity of exactly the symptoms ACP-204 is meant to treat, and the six-week window is typical for demonstrating acute control of psychosis. A meaningful, statistically significant reduction in that score versus placebo is what the entire master protocol is engineered to detect.
The scale of the program is itself a statement of intent. At 1,074 planned participants spread across three substudies, this is not an exploratory dabble; it is a fully resourced push toward an approvable package. The seamless enrollment between the dose-finding and confirmatory portions also reduces a common failure mode, where promising Phase 2 results stall for months or years before a confirmatory study can be stood up, leaking momentum and sometimes losing investigators and sites in the gap. By keeping the machinery running continuously and pre-specifying how doses graduate from Substudy 1 into the confirmatory Substudies 2A and 2B, ACADIA is trying to compress the timeline without sacrificing the rigor that two independent confirmatory studies provide.
What a positive result would mean
The study started on November 14, 2023, with an estimated primary completion date of January 2028. A clean win would mean ACP-204 significantly lowers hallucination and delusion severity at week 6 across the dose-finding and confirmatory substudies, with a tolerability profile clean enough for a frail, elderly population. That would be a genuine event in neuropsychiatry: a purpose-built treatment for Alzheimer's disease psychosis where today clinicians improvise with drugs never approved for the indication.
The cautions are inherent to the field. Psychosis endpoints rely on subjective clinical rating scales, and placebo responses in dementia trials can be large and noisy, which is partly why ACADIA chose quadruple masking and a confirmatory two-study design. Safety scrutiny will be intense given the population's vulnerability. And a six-week primary endpoint establishes acute efficacy, not the long-term durability and safety that real-world use demands. Still, with more than a thousand patients enrolled and a mechanistically targeted drug, NCT06159673 is one of the more closely watched programs in dementia care, and January 2028 is when its central question comes due.